Overview

SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This trial aims to prospectively assess the safety and efficiency of SHR7390 in metastatic castration-resistant prostate cancer
Phase:
Phase 2
Details
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School